Neuren Acquires Hamilton, Gets Phase II CNS Drug

Morrison, Trista
August 2007
BioWorld Today;8/1/2007, Vol. 18 Issue 148, p1
The article reports that Neuren Pharmaceuticals Ltd. has acquired Hamilton Pharmaceuticals Inc. The deal has yet to be approved by Neuren shareholders. According to Lawrence Glass, Neuren's executive vice president of biology, the company is excited with Hamilton's drug for central nervous system disorders, Motiva. The financial terms of the deal are disclosed.


Related Articles

  • Neuren Gets Hamilton, CNS Drug Motiva For $4.4 M.  // Bioworld Week;8/6/2007, Vol. 15 Issue 32, p4 

    The article reports on the acquisition of Hamilton Pharmaceuticals Inc. by Neuren Pharmaceuticals for $4.4 million in the U.S. Neuren's acquisition of Hamilton leads the firm to gain access to Hamilton's Phase II drug for central nervous system disorders, Motiva. In addition, Neuren will pay...

  • A good year that ended with lots of excitement. Goldblatt // Business News New Jersey;01/04/2000, Vol. 13 Issue 1, p33 

    Reports on the mergers and takeovers in the United States pharmaceutical industry. Opposition of Pfizer to the planned merger of American Home Products with Warner-Lambert; Proposal for the alliance of Pharmacia and Upjohn with Monsanto; Comparison of the revenues of the bigger drug companies. ...

  • Healthcare.  // Investment Dealers' Digest;07/17/2000, Vol. 66 Issue 29, p48 

    Reports developments in the pharmaceutical industry in the United States as of July 2000. Amount for the planned purchase PCS HealthSystem by Advance Paradigm Inc.; Plan of Millennium Pharmaceuticals Inc. to purchase Cambridge Discovery Chemistry; Impact of the planned purchase for Advanced...

  • Following the Megadeal Decade, Drug Makers Face a Rockier Road to Growth. Harrison, Joan // Mergers & Acquisitions: The Dealermaker's Journal;Mar2002, Vol. 37 Issue 3, p21 

    Focuses on the merger activities in the pharmaceutical industry in the U.S. Effects of biotechnology on drug company acquisitions; Impact of the scrapping of the pooling-of-interest accounting on drug industry dealmaking; Significance of acquisitions on cost reductions.

  • Outsourcing Outlook. Miller, Jim // Pharmaceutical Technology North America;Sep2001, Vol. 25 Issue 9, p96 

    Focuses on the projections for the mergers activity in the pharmaceutical industry in the U.S. Contract packaging companies with likelihood of consolidating; Capital needs of dose manufacturing; Revenues of the contract laboratory services sector.

  • Outsourcing Outlook. Miller, Jim // Pharmaceutical Technology North America;Dec2001, Vol. 25 Issue 12, p52 

    Focuses on the biomanufacturing and parenteral fill-finish capacity in pharmaceutical industry in the U.S. Acquisition of sterile manufacturing Schering-plough by Cardinal Health; Regulatory and operating problems of Catalytic Pharmaceuticals; Manufacturing contracts between Pathen and Famar.

  • Pharmaceutical market in flux. Martinez, Marialba // Caribbean Business;12/5/2002, Vol. 30 Issue 49, p14 

    Presents an overview of the pharmaceutical market and industry in Puerto Rico for the year 2002. Financial performance of companies; Acquisitions; Sales; Operations.

  • Good times ahead for Germany? Gopal, Kevin // Pharmaceutical Executive;Nov98, Vol. 18 Issue 11, p30 

    Provides information on the condition of German pharmaceutical industry in 1998. Alliance announced by Bayer in 1998; Increase in sales posted by Merck company; Companies which launched new products in 1998.

  • Company News.  // Pharmaceutical Executive;Jun99, Vol. 19 Issue 6, p134 

    Presents updates on pharmaceutical companies. Information on the merger of Rhone-Poulenc Rorer and Hoechst AG into Aventis; Retirement of Immunex Corporation's chief financial officer; Details on Zeneca's resource program for people with psychosis-related disorders and their families.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics